Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

PHASE3TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Hyperlipoproteinemia Type III
Interventions
DRUG

torcetrapib/atorvastatin

DRUG

atorvastatin

DRUG

fenofibrate

Trial Locations (27)

13210

Pfizer Investigational Site, Syracuse

14224

Pfizer Investigational Site, West Seneca

14618

Pfizer Investigational Site, Rochester

18960

Pfizer Investigational Site, Sellersville

29651

Pfizer Investigational Site, Greer

32779

Pfizer Investigational Site, Longwood

33021

Pfizer Investigational Site, Hollywood

38105

Pfizer Investigational Site, Memphis

38654

Pfizer Investigational Site, Olive Branch

49002

Pfizer Investigational Site, Portage

49024

Pfizer Investigational Site, Portage

53719

Pfizer Investigational Site, Madison

84108

Pfizer Investigational Site, Salt Lake City

90272

Pfizer Investigational Site, Pacific Palisades

91604

Pfizer Investigational Site, Studio City

92648

Pfizer Investigational Site, Huntington Beach

92780

Pfizer Investigational Site, Tustin

92804

Pfizer Investigational Site, Anaheim

92868

Pfizer Investigational Site, Orange

98104

Pfizer Investigational Site, Seattle

96859-5000

Pfizer Investigational Site, Tripler Army Medical Center

04074

Pfizer Investigational Site, Scarborough

N6A 5K8

Pfizer Investigational Site, London

G7H 5H6

Pfizer Investigational Site, Chicoutimi

H1T 1C8

Pfizer Investigational Site, Montreal

H2W 1R7

Pfizer Investigational Site, Montreal

G1V 4M6

Pfizer Investigational Site, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00145431 - Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder. | Biotech Hunter | Biotech Hunter